Nuwellis (NUWE) 10-K 3 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 24, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity File Number	001-35312
Entity Registrant Name	NUWELLIS, INC.
Entity Central Index Key	0001506492
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0533453
Entity Address, Address Line One	12988 Valley View Road
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	345-4200
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NUWE
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 6.2
Entity Common Stock, Shares Outstanding		1,206,932
Auditor Firm ID	23
Auditor Name	Baker Tilly US, LLP
Auditor Location	Minneapolis, Minnesota

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 17,737	$ 8,742
Marketable securities	569	15,463
Accounts receivable	1,406	750
Inventories, net	2,661	2,843
Other current assets	396	328
Total current assets	22,769	28,126
Property, plant and equipment, net	980	1,188
Operating lease right-of-use asset	903	1,082
Other assets	21	21
TOTAL ASSETS	24,673	30,417
Current liabilities
Accounts payable and accrued liabilities	2,245	1,414
Accrued compensation	2,161	1,664
Current portion of operating lease liability	196	167
Current portion of finance lease liability	28	26
Other current liabilities	58	36
Total current liabilities	4,688	3,307
Common stock warrant liability	6,868	0
Operating lease liability	760	956
Finance lease liability	0	28
Other long-term liability	0	179
Total liabilities	12,316	4,470
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common stock as of December 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 536,394 and 105,376, respectively	0	0
Additional paid-in capital	279,736	278,874
Accumulated other comprehensive income:
Foreign currency translation adjustment	(18)	(11)
Unrealized gain (loss) on marketable securities	56	(24)
Accumulated deficit	(267,417)	(252,892)
Total stockholders' equity	12,357	25,947
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	24,673	30,417
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	0	0
Series I Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	39,969,873	39,969,873
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	536,394	105,376
Common stock, shares outstanding (in shares)	536,394	105,376
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	30,000	30,000
Preferred stock, shares outstanding (in shares)	0	0
Series F Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	127	127
Preferred stock, shares issued (in shares)	127	127
Preferred stock, shares outstanding (in shares)	127	127
Series I Convertible Preferred Stock [Member]
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,049,280	0
Preferred stock, shares issued (in shares)	1,049,280	0
Preferred stock, shares outstanding (in shares)	1,049,280	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Net sales	$ 8,543	$ 7,921
Cost of goods sold	3,788	3,430
Gross profit	4,755	4,491
Operating expenses:
Selling, general and administrative	17,584	19,039
Research and development	4,342	4,978
Total operating expenses	21,926	24,017
Loss from operations	(17,171)	(19,526)
Other income (expense), net
Other income (expense), net	75	(19)
Financing expense	(9,247)	0
Change in fair value of warrant liability	11,827	0
Loss before income taxes	(14,516)	(19,545)
Income tax expense	(9)	(9)
Net loss	$ (14,525)	$ (19,554)
Basic loss per share (in dollars per share)	$ (83.55)	$ (285.36)
Diluted loss per share (in dollars per share)	$ (83.55)	$ (285.36)
Weighted average shares outstanding - basic (in shares)	174	69
Weighted average shares outstanding - diluted (in shares)	174	69
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	$ 80	$ (24)
Unrealized foreign currency translation adjustment	(7)	(4)
Total comprehensive loss	$ (14,452)	$ (19,582)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2020	$ 0	$ 249,663	$ (7)	$ (233,338)	$ 16,318
Balance (in shares) at Dec. 31, 2020	27,360
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(19,554)	(19,554)
Unrealized foreign currency translation adjustment	0	0	(4)	0	(4)
Unrealized gain (loss) on marketable securities	0	0	(24)	0	(24)
Stock-based compensation, net	$ 0	1,314	0	0	1,314
Stock-based compensation, net (in shares)	0
Issuance of common stock, net	$ 0	27,896	0	0	27,896
Issuance of common stock, net (in shares)	78,014
Exercise of warrants	$ 0	1	0	0	1
Exercise of warrants (in shares)	2
Balance at Dec. 31, 2021	$ 0	278,874	(35)	(252,892)	25,947
Balance (in shares) at Dec. 31, 2021	105,376
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ 0	0	0	(14,525)	(14,525)
Unrealized foreign currency translation adjustment	0	0	(7)	0	(7)
Unrealized gain (loss) on marketable securities	0	0	80	0	80
Stock-based compensation, net	$ 0	862	0	0	862
Stock-based compensation, net (in shares)	0
Issuance of common stock, net	$ 0	0	0	0	0
Issuance of common stock, net (in shares)	209,940
Conversion of preferred stock into common stock	$ 0	0	0	0	0
Conversion of preferred stock into common stock (in shares)	221,078
Balance at Dec. 31, 2022	$ 0	$ 279,736	$ 38	$ (267,417)	$ 12,357
Balance (in shares) at Dec. 31, 2022	536,394

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Activities
Net loss	$ (14,525)	$ (19,554)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization	372	488
Stock-based compensation expense, net	862	1,314
Change in fair value of warrant liability	(11,827)	0
Financing expense	9,247	0
Net realized and unrealized gains on marketable securities	124	13
Changes in operating assets and liabilities:
Accounts receivable	(656)	155
Inventory	140	(143)
Other current assets	(68)	(91)
Other assets and liabilities	(96)	186
Accounts payable and accrued expenses	1,278	(211)
Net cash used in operating activities	(15,149)	(17,843)
Investing activities:
Purchases of marketable securities	0	(18,850)
Proceeds from sales of marketable securities	14,850	3,350
Purchase of property and equipment	(122)	(219)
Net cash provided (used) in investing activities	14,728	(15,719)
Financing activities:
Proceeds from public stock offerings, net	9,449	27,896
Proceeds from warrant exercises	0	1
Payments on finance lease liability	(26)	(26)
Net cash provided by financing activities	9,423	27,871
Effect of exchange rate changes on cash	(7)	(4)
Net increase in cash and cash equivalents	8,995	(5,695)
Cash and cash equivalents - beginning of year	8,742	14,437
Cash and cash equivalents - end of year	17,737	8,742
Supplemental schedule of non-cash activities
Inventory transferred to property, plant and equipment	42	257
Operating right-of-use asset recorded as an operating lease liability	0	901
Supplemental cash flow information
Cash paid for income taxes	$ 9	$ 11

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Nature of Business and Significant Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1—Nature of Business and Significant Accounting Policies Nature of Business Nuwellis, Inc. (the “Company”) is a medical technology company focused on developing, manufacturing and commercializing the Aquadex FlexFlow® and Aquadex SmartFlow® systems (collectively, the “Aquadex System”) for ultrafiltration therapy. The Aquadex SmartFlow® system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more, whose fluid overload is unresponsive to medical management, including diuretics In August 2016, the Company acquired the business associated with the Aquadex System (the “Aquadex Business”) from a subsidiary of Baxter International, Inc. (“Baxter”), and refocused its strategy to fully devote its resources to the Aquadex Business. On April 27, 2021, the Company announced that it was changing its name from CHF Solutions, Inc. to Nuwellis, Inc. to reflect the expansion of its customer base from treating fluid imbalance resulting from congestive heart failure to also include critical care and pediatrics applications Going Concern The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2022 and 2021, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of December 31, 2022, the Company had an accumulated deficit of $267.4 million, and it expects to incur losses for the immediate future. To date, the Company has been funded by equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through at least twelve months from the report date. The Company became a revenue-generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, investing in clinical research and new product development, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing, and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability. During 2021 and through December 31, 2022, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $37.3 million after deducting the underwriting discounts and commissions and other costs associated with the offerings . See Note 4—Stockholders’ Equity for additional related disclosure The Company believes that its existing capital resources will be sufficient to support its operating plan through December 31, 2023. However, the Company may seek to raise additional capital to support its growth or other strategic initiatives through debt, equity, or a combination thereof. There can be no assurance we will be successful in raising additional capital. Basis of Presentation The accompanying consolidated financial statements include the accounts of Nuwellis, Inc. and its wholly owned subsidiary, Sunshine Heart Ireland Limited. All intercompany accounts and transactions between consolidated entities have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and term deposits with original maturities of three months or less. The carrying value of these instruments approximates fair value. The balances, at times, may exceed federally insured limits. The Company has not experienced any losses on its cash and cash equivalents. Marketable securities The Company’s marketable securities typically consist of investment-grade, U.S. dollar-denominated fixed and floating-rate debt, which are classified as available-for-sale and included in current assets. Most marketable securities mature within twelve months from their date of purchase and generally are intended to fund current operations. Securities are valued based on market prices for similar assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of shareholders’ equity in accumulated other comprehensive income (loss). Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis and impairment is indicated, it must be determined whether the impairment is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of shareholders’ equity in accumulated other comprehensive gain (loss). There were no other than temporary unrealized losses as of December 31, 2022. Accounts Receivable Accounts receivables are unsecured, recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and management’s evaluation of specific accounts, and it will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration in the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of December 31, 2022 or December 31, 2021. As of December 31, 2022, two customers represented 15% and 10% of the total accounts receivable balance. As of December 31, 2021, two customers represented 12% and 11% of the total accounts receivable balance. Inventories Inventories are recorded at the lower of cost or net realizable value using the first-in, first-out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. On a regular basis, the Company reviews its inventory and identifies that which is excess, slow moving, and obsolete by considering factors such as inventory levels and expected product life. A reserve is established for any identified excess, slow moving, and obsolete inventory through a charge to cost of goods sold. Inventories consisted of the following as of December 31: (Dollars in thousands) 2022 2021 Finished Goods $ 993 $ 1,527 Work in Process 204 276 Raw Materials 1,609 1,281 Inventory Reserves (145 ) (241 ) Total $ 2,661 $ 2,843 Other Current Assets Other current assets represent prepayments and deposits made by the Company. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is computed based upon the estimated useful life of the respective asset. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Repairs and maintenance cost is expensed as incurred. The cost and accumulated depreciation of property, plant and equipment retired or otherwise disposed of is removed from the related accounts, and any residual values are charged to expense. Depreciation expense has been calculated using the following estimated useful lives: Production Equipment 3-7 years Office Furniture and Fixtures 3-5 years Computer Software and Equipment 3-4 years Loaners and demo equipment 1-5 years Leasehold improvements 3-5 years Depreciation expense was $372,000 and $488,000 for the years ended December 31, 2022 and 2021, respectively. Property, plant and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group, further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the fair value of the asset or asset group is exceeded by its carrying amount. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets or asset groups, and accordingly, actual results could vary significantly from such estimates. The Company continues to report operating losses and negative cash flows from operations, both of which it considers to be indicators of potential impairment. Therefore, the Company evaluates its long-lived assets for potential impairment at each reporting period. The Company has concluded that its cash flows from the various long-lived assets are highly interrelated and, as a result, the Company consists of a single asset group. As the Company expects to continue incurring losses in the foreseeable future, the undiscounted cash flow step was bypassed, and the Company proceeded to fair value the asset group. . There have been no impairment losses recognized for the years ended December 31, 2022 or 2021. Accounts Payable and Accrued Liabilities Accrued liabilities includes amounts accrued but not invoiced related to payments owed for licensing agreements, director fees, and others. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Foreign Currency Translation Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Assets and liabilities of foreign operations are translated at period-end exchange rates with the impacts of foreign currency translation recorded in cumulative translation adjustment, a component of accumulated other comprehensive income. Foreign currency transactions gains and losses are included in other expense, net in the consolidated statements of operations and other comprehensive loss. Stock-Based Compensation The Company recognizes all share-based payments to employees, directors, and consultants, including grants of stock options and common stock awards, in the consolidated statement of operations and comprehensive loss as an operating expense based on their fair values as established at the grant date. Equity instruments issued to non-employees include common stock awards or warrants to purchase shares of our common stock. These common stock awards or warrants are either fully vested and exercisable at the date of grant or vest over a certain period during which services are provided. The Company expenses the fair market value of fully vested awards at the time of grant, and of unvested awards over the period in which the related services are received. The Company computes the estimated fair values of stock options using the Black-Scholes option pricing model. Market price at the date of grant is used to calculate the fair value of common stock awards. Stock-based compensation expense is based on awards ultimately expected to vest and is reduced for forfeitures. See Note 5—Stock-Based Compensation, for further information regarding the assumptions used to calculate the fair value of stock-based compensation. Income Taxes Deferred income taxes are provided on a liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Loss per share Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. The net loss allocable to common stockholders for the year ended December 31, 2021, includes a deemed dividend of $75,000 that resulted from the change in the exercise price of warrants as a result of the March 2021 and September 2021 public offerings. (see Note 4 — Stockholders’ Equity) Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each year presented: December 31, 2022 2021 Stock options 10,485 7,481 Warrants to purchase common stock 679,244 16,299 Series F convertible preferred stock 5,080 50,800 Series I convertible preferred stock 10,493 — Total 705,302 74,580 The following table reconciles reported net loss with reported net loss per share for the years ended December 31: (in thousands, except per share amounts) 2022 2021 Net loss $ (14,525 ) $ (19,545 ) Deemed dividend to preferred stockholders (see Note 4) — (75 ) Net loss after deemed dividend (14,525 ) (19,620 ) Weighted average shares outstanding 174 69 Basic and diluted loss per share $ (83.55 ) $ (285.36 ) Research and Development Research and development (R&D) costs include activities related to development, design, and testing improvements of the Aquadex System and potential related new products. These R&D costs also include expenses related to clinical research that the Company may sponsor or conduct to enhance understanding of the product and its use. R&D costs are expensed as incurred. Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, “Financial Instruments – Credit Losses.” This ASU added a new impairment model (known as the current expected credit loss (“CECL”) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses. The CECL model applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses, and entities will need to measure expected credit losses on assets that have a low risk of loss. As a smaller reporting company pursuant to Rule 12b-2 of the Securities Exchange Act of 1934, as amended, these changes become effective for the Company on January 1, 2023. Management has evaluated the potential impact of these changes on the consolidated financial statements of the Company and does not anticipate it will have any impact to the Company’s consolidated financial statements. The Company evaluates subsequent events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2022
Revenue Recognition [Abstract]
Revenue Recognition	Note 2 – Revenue Recognition Net Sales The Company sells its products in the United States primarily through a direct salesforce. Customers who purchase the Company’s products include hospitals and clinics throughout the United States. In countries outside the United States, the Company sells its products through a limited number of specialty healthcare distributors in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, United Arab Emirates, and the United Kingdom. These distributors resell the Company’s products to hospitals and clinics in their respective geographies. Revenue from product sales is recognized when the customer or distributor obtains control of the product, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. The Company’s standard shipping terms are FOB shipping point unless the customer requests that control and title to the inventory transfer upon delivery. Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The majority of the Company’s contracts have a single performance obligation and are short term in nature. The Company has entered into extended service plans with customers, which are recognized over time. This revenue represents less than 1% of net sales for each of the years ended December 31, 2022 and 2021. The unfulfilled performance obligations related to these extended service plans are included in deferred revenue, which is included in other current liabilities on the consolidated balance sheets. The majority of the deferred revenue is expected to be recognized within one year. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Revenue includes shipment and handling fees charged to customers. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold. Product Returns: believes that future returns of its products will be minimal.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 3—Property, Plant and Equipment Property, plant and equipment were as follows: (in thousands) December 31, 2022 December 31, 2021 Production Equipment $ 1,360 $ 1,321 Loaners and Demo Equipment 1,444 1,364 Computer Software and Equipment 719 714 Office Furniture & Fixtures 375 364 Leasehold Improvements 253 245 Total 4,151 4,008 Accumulated Depreciation (3,171 ) (2,820 ) $ 980 $ 1,188

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 4—Stockholders’ Equity Series F Convertible Preferred Stock The offering was comprised of Series F convertible preferred stock, convertible into shares of the Company’s common stock at a conversion price of $189,000 per share. Each share of Series F convertible preferred stock was accompanied by a Series 1 warrant, which was to expire on the first anniversary of its issuance, to purchase 16 shares of the Company’s common stock at an exercise price of $189,000 per share, and a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 4 shares of the Company’s common stock at an exercise price of $189,000 per share. The Series F convertible preferred stock has full ratchet price-based anti-dilution protection, subject to customary carve-outs, in the event of a down-round financing at a price per share below the conversion price of the Series F convertible preferred stock (which protection will expire if, during any 20 of 30 consecutive trading days, the volume weighted average price of the Company’s common stock exceeds 300% of the then-effective conversion price of the Series F convertible preferred stock and the daily dollar trading volume for each trading day during such period exceeds $200,000). The exercise price of the warrants is fixed and does not contain any variable pricing features, nor any price based anti-dilutive features, apart from customary adjustments for stock splits, combinations, reclassifications, stock dividends or fundamental transactions. A total of 18,000 shares of Series F convertible preferred stock convertible into 96 shares of common stock and warrants to purchase 191 shares of common stock were issued in the offering. Effective March 12, 2019, the conversion price of the Series F convertible preferred stock was reduced from $89,040 to $15,750, the per share price to the public of the Series G convertible preferred stock issued in the March 2019 Offering. Effective October 25, 2019, the conversion price of the Series F convertible preferred stock was reduced from $15,750 to $4,230, and on November 6, 2019, from $4,230 to $2,983, the per share price to the public in the October and November 2019 transactions, respectively. Effective January 28, 2020, the conversion price of the Series F convertible preferred stock was reduced from $2,983 to $1,650, the per share price to the public of the Series H convertible preferred stock which closed in an underwritten public offering on January 28, 2020, described below. Effective March 23, 2020, the conversion price of the Series F convertible preferred stock was reduced from $1,650 to $900, the per share price to the public in the March 2020 transaction, described below. In connection with the September 2021 offering, the conversion price of the Series F convertible preferred stock was reduced from $550 to $250, the per share price to the public in the September 2021 offering, described below. In connection with the October 2022 offering, the conversion price of the Series F convertible preferred stock was reduced from $250 to $25, the per share price to the public in the October 2020 offering, described below. As of December 31, 2022, and December 31, 2021, 127 shares of the Series F convertible preferred stock remained outstanding. Series H Convertible Preferred Stock and January 2020 Offering: The January 2020 Offering was comprised of 2,015 shares of common stock priced at $1,650 per share and 115,173 shares of Series H convertible preferred stock, convertible into common stock at $1,650 per share, . Each share of Series H convertible preferred stock and each share of common stock was accompanied by a warrant to purchase common stock. The warrants are exercisable into 5,855 shares of common stock. As of December 31, 2020, all 115,173 shares of the Series H convertible preferred stock had been converted into common stock and none remained outstanding. As of December 31, 2020, warrants to purchase 4,552 shares of common stock had been exercised for total cash proceeds of $4.1 million. March 2020 Offering: five and a half years April 2020 Offering five and a half years May 2020 Offering five and a half years August 2020 Offering 10,647 shares of common stock priced at $1,350 per share. Each share of common stock was accompanied by a warrant to purchase common stock. The warrants are exercisable into 10,647 shares of common stock. March 2021 Offering In connection with the March 2021 Offering, the conversion price of the Series F convertible preferred stock was reduced from $900 to $550, the per share price to the public in the March 2021 Offering. In addition, the exercise price of the common stock warrants issued in connection with the January 2020 Offering was reduced from $900 to $550, the per share price to the public in the March 2021 Offering. September 2021 Offering In connection with the September 2021 Offering, the conversion price of the Series F convertible preferred stock was reduced from $550 to $250, the per share price to the public in the September 2021 Offering. In addition, the exercise price of the common stock warrants issued in connection with the January 2020 Offering was reduced from $550 to $250, the per share price to the public in the September 2021 Offering. October 2022 Offering The offering was comprised of (1) 209,940 Class A Units, priced at a public offering price of per Class A Unit, with each Class A Unit consisting of one share of common stock and 1.5 warrants to purchase one share of common stock at an exercise price of per share, and (2) 23,157,124 Class , priced at a public offering price of per Class , with each Class consisting of one share of Series I convertible preferred stock, convertible into one share of common stock and 1.5 warrants to purchase one share of common stock a .00 exercise price. The warrants became exercisable beginning on the effective date of a reverse stock split in an amount sufficient to permit the exercise in full of the warrants, contingent upon stockholder approval of such reverse stock split and of the exercisability of the warrants under Nasdaq rules, and will expire on the sixth anniversary of the initial exercise date. On December 8, 2022, following a special meeting of stockholders, the Company’s board of directors approved a one-for-one hundred “Reverse Stock Split” ). On December 9, 2022, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment” ) to effect the Reverse Stock Split. The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on December 9, 2022, and the Company’s common stock began trading on a split-adjusted basis when the market opened on December 12, 2022. The conversion price of the preferred stock issued in the transaction was fixed and does not contain any variable pricing feature or any price-based anti-dilutive feature. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock) or liquidation preference and, subject to limited exceptions, has no voting rights. The securities comprising the units are immediately separable and were issued separately. In connection with the October 2022 Offering, the conversion price of the Series F convertible preferred stock was reduced from $250 to $25, the per share price to the public in the October 2022 Offering. In addition, the exercise price of the common stock warrants issued in connection with the January 2020 Offering was reduced from $250 to $25, the per share price to the public in the October 2022 Offering. Placement Agent Fees Market-Based Warrants Reverse Stock Split 1-for-50 1-for-100 1-for-100

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 5— Stock-Based Compensation Stock Options and Restricted Stock Awards The Company has various share-based compensation plans, including the Third Amended and Restated 2017 Equity Incentive Plan, the 2013 Non-Employee Directors’ Equity Incentive Plan and the 2021 Inducement Plan (collectively, the “Plans” The Company recognized stock-based compensation expense related to grants of stock options and common stock awards to employees, directors and consultants of $862,000 and $1.3 million during the years ended December 31, 2022 and 2021, respectively. The following table summarizes the stock-based compensation expense that was recognized in the consolidated statements of operations for the years ended December 31, (Dollars in thousands) 2022 2021 Selling, general and administrative $ 784 $ 1,171 Research and development 78 143 Total $ 862 $ 1,314 The majority of the common stock awards and options to purchase common stock vest on the anniversary of the date of grant, which ranges from one Stock Options The following is a summary of the Plans’ stock option activity during the years ended December 31: 2022 2021 Options Outstanding Weighted Average Exercise Price Options Outstanding Weighted Average Exercise Price Beginning Balance 7,481 $ 656.05 144 $ 40,534.00 Granted 5,833 83.96 9,081 444.83 Exercised — — — — Forfeited/expired (2,829 ) 410.34 (1,744 ) 2,332.06 Outstanding at December 31 10,485 $ 404.08 7,481 $ 656.05 Vested at December 31 3,531 $ 727.26 409 $ 4,218.40 For options outstanding and vested at December 31, 2022 and 2021, the weighted average remaining contractual life was 8.79 years and 8.63 years, respectively. There were no option exercises in 2022 or 2021. The total fair value of options that vested in 2022 and 2021 was $1.1 million, and $0.7 million, respectively, at the fair value of the options as of the date of grant. Valuation Assumptions The Company has not historically paid cash dividends to its stockholders and currently does not anticipate paying any cash dividends in the foreseeable future. As a result, the Company has assumed a dividend yield of 0%. The risk-free interest rate is based upon the rates of U.S. Treasury bills with a term that approximates the expected life of the option. Since the Company has limited historical exercise data to reasonably estimate the expected life of its option awards, the expected life is calculated using a simplified method. Expected volatility is based on historical volatility of the Company’s stock. The following table provides the weighted average assumptions used in the Black-Scholes option pricing model for the years ended December 31: 2022 2021 Expected dividend yield 0 % 0 % Risk-free interest rate 2.13 % 1.19 % Expected volatility 132.48 % 131.03 % Expected life (in years) 6.15 6.21 The weighted-average fair value of stock options granted in 2022 and 2021 was $76.05 and $396.17, respectively. As of December 31, 2022, the total compensation cost related to all non-vested stock option awards not yet recognized was approximately $1.3 million and is expected to be recognized over the remaining weighted-average life of 2.54 years. Warrants

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	Note 6—Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, marketable securities, and warrants. Pursuant to the requirements of ASC Topic 820 “Fair Value Measurement,” ● Level 1 ● Level 2 ● Level 3 All cash equivalents and marketable securities are considered Level 1 measurements for all periods presented. The available-for-sale marketable securities primarily consist of investment-grade, U.S. dollar-denominated fixed and floating-rate debt, measured at fair value on a recurring basis. 2022 2021 (Dollars in thousand s Fair Value Level 1 Fair Value Level 1 Marketable securities $ 569 $ 569 $ 15,463 $ 15,463 The fair value of the Company’s common stock warrant liability related to the investor warrants issued in the October 2022 public offering, was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy. The following is a roll-forward of the fair value of Level 3 warrants: (in thousands) October 18, 2022 warrant issuance $ 18,695 Change in fair value (11,827 ) Ending balance December 31, 2022 $ 6,868 Fair values were calculated using the following assumptions: Oct. 18, 2022 Dec. 31, 2022 Risk-free interest rates, adjusted for continuous compounding 4.16 % 3.97 % Term (years) 6.18 6.11 Expected volatility 141.5 % 145.3 % Dates and probability of future equity raises various various A significant change in the inputs used for the Monte Carlo and Black Scholes valuation models, such as the expected volatility, risk-free interest rate, or probability of future equity financings, in isolation, would result in significantly higher or lower fair value measurements. In combination, changes in these inputs could result in a significantly higher or lower fair value measurement if the input changes were to be aligned or could result in a minimally higher or lower fair value measurement if the input changes were of a compensating nature.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Income Taxes	Note 7—Income Taxes Domestic and foreign income (loss) before income taxes consists of the following for the years ended December 31: (in thousands) 2022 2021 Domestic $ (14,551 ) $ (19,582 ) Foreign 35 37 Loss before income taxes $ (14,516 ) $ (19,545 ) The components of income tax expense consist of the following for the years ended December 31: (in thousands) 2022 2021 Current: United States and state $ — $ — Foreign, net (9 ) (9 ) Deferred: United States and state — — Foreign — — Total income tax expense $ (9 ) $ (9 ) Actual income tax expense differs from statutory federal income tax expense as follows for the years ended December 31: (in thousands) 2022 2021 Statutory federal income tax benefit $ 3,048 $ 4,109 State tax benefit, net of federal taxes 783 560 Foreign tax (1 ) (1 ) Nondeductible/nontaxable items 548 (220 ) Other (41 ) 406 Valuation allowance (increase) decrease (4,346 ) (4,863 ) Total income tax expense $ (9 ) $ (9 ) Deferred taxes consist of the following as of December 31: (in thousands) 2022 2021 Deferred tax assets: Noncurrent: Accrued leave $ 397 $ 59 Stock based compensation 360 368 Net operating loss carryforward 45,405 42,363 Other 42 131 Intangibles 1,786 723 R&D credit carryforward 531 531 Total deferred tax assets 48,521 44,175 Less: valuation allowance (48,521 ) (44,175 ) Total $ — $ — As of December 31, 2022, the Company had federal net operating loss (“NOL”) 2024 2038 The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a valuation allowance for U.S. and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. For the years ended December 31, 2022, and 2021, the valuation allowance increased by $4.3 million and $4.9 million, respectively. The current year increase was primarily due to the federal and state net operating losses generated. During 2022 and 2021, the Company believes it experienced an ownership change as defined in Section 382 of the Internal Revenue Code, which will limit the ability to utilize the Company’s net operating losses (NOLs). The Company may have experienced additional ownership changes in earlier years further limiting the NOL carryforwards that may be utilized. The Company has not yet completed a formal Section 382 analysis. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change. The accounting guidance related to uncertain tax positions prescribes a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company had no material uncertain tax positions as of December 31, 2022 or 2021. The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At December 31, 2022 and 2021, the Company recorded no accrued interest or penalties related to uncertain tax positions. The tax years ended December 31, 2019 through December 31, 2022 remain open to examination by the Internal Revenue Service and by the various states where the Company is subject to taxation. Additionally, the returns of the Company’s Australian (through November 2020) and Irish subsidiaries are subject to examination by tax authorities of those jurisdictions for the tax years ended and subsequent to June 30, 2017 and December 31, 2017, respectively.

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2022
Operating Leases [Abstract]
Operating Leases	Note 8—Operating Leases The Company leases a 23,000 square foot facility located in Eden Prairie, Minnesota for The cost components of the Company’s operating lease were as follows for the year ended December 31: (in thousands) 2022 2021 Operating lease cost $ 238 $ 219 Variable lease cost 127 123 Total $ 365 $ 342 Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased office and manufacturing space. Maturities of our lease liability for the Company’s operating lease are as follows as of December 31: (in thousands) 2022 2023 $ 249 2024 257 2025 264 2026 272 2027 69 Total lease payments 1,111 Less: Interest (155 ) Present value of lease liability $ 956 As of December 31, 2022, and 2021, the remaining lease terms were 4.25 and 5.25 years, respectively, and discount rates were 6.25% and 7.5% respectively. For the years ended December 31, 2022, and 2021, the operating cash outflows from the Company’s operating lease for office and manufacturing space were $238,000 and $219,000, respectively.

Finance Lease Liability

Finance Lease Liability	12 Months Ended
	Dec. 31, 2022
Finance Lease Liability [Abstract]
Finance Lease Liability	Note 9—Finance Lease Liability In 2020, the Company entered into lease agreements to finance equipment valued at $98,000. The equipment consisted of computer hardware and audio-visual equipment and is included in Property, Plant and Equipment

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 10—Commitments and Contingencies Employee Retirement Plan The Company has a 401(k) plan that provides a retirement benefit to substantially all full-time U.S. employees. Eligible employees may contribute a percentage of their annual compensation, subject to Internal Revenue Service limitations, with the Company matching a portion of the employees’ contributions at the discretion of the Company. Matching contributions totaled $185,000 and $255,000 for the years ended December 31, 2022 and 2021, respectively. Non-refundable Technology License Fee On June 24, 2021, the Company entered into a research and development collaboration agreement with Koronis Biomedical Corporation (KBT) to design and develop an integrated continuous renal replacement therapy device. This agreement became effective on August 5, 2021, when KBT received approval of a $1.7 million grant from the National Institutes of Health (NIH) to support this project. As part of this agreement, the Company will pay KBT a non-refundable technology license fee of $428,160, payable in twelve equal monthly installments commencing on June 1, 2022. The Company has recorded a liability for the non-refundable technology license fee, with $178,400 included in Current Accounts Payable at December 31, 2022. The full amount of $428,160 was expensed and included in the Research and Development Expense line for the year ended December 31, 2021.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11—Related Party Transactions There were no related party transactions requiring disclosure during the year ended December 31, 2022 and 2021.

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2022
Segment and Geographic Information [Abstract]
Segment and Geographic Information	Note 12—Segment and Geographic Information The Company has one reportable segment, fluid management. At December 31, 2022 and 2021, long-lived assets were located primarily in the United States.

Revision and Immaterial Correct

Revision and Immaterial Correction of an Error in Previously Issued Financial Statements	12 Months Ended
	Dec. 31, 2022
Revision and Immaterial Correction of an Error in Previously Issued Financial Statements [Abstract]
Revision and Immaterial Correction of an Error in Previously Issued Financial Statements	Note 13 Revision and Immaterial Correction of an Error in Previously Issued Financial Statements The Company identified an error related to the classification and disclosures of marketable securities in our consolidated financial statements as of and for the year ended December 31, 2021 as reported on Form 10-K. In our December 31, 2021 consolidated financial statements, we incorrectly classified short term marketable securities as a cash and cash equivalents on the consolidated balance sheet. There was no change to the total current assets on the consolidated balance sheet. Additionally, we recorded an unrealized gain in other income on the consolidated statement of operations. This unrealized gain should have been recorded as accumulated other comprehensive income in the consolidated statement of operations and comprehensive loss and the consolidated statements of stockholders’ equity. This correction also impacts the consolidated statement of cash flows, as the purchase of these securities and redemption of these securities would be shown in the investing activities section. In accordance with ASC 250, Accounting Changes and Error Corrections The tables below present the effect of the financial statement adjustments related to the revision discussed above of the Company’s previously reported financial statements as of and for the periods ended December 31, 2021. The effect of the immaterial correction of an error on our previously filed audited consolidated financial statements as of December 31, 2021 and for the year then ended is as follows: (in thousands) December Consolidated Balance Sheet As reported Adjustment As revised Cash and cash equivalents $ 24,205 $ (15,463 ) $ 8,742 Marketable securities - 15,463 15,463 Total Current Assets 28,126 - 28,126 Consolidated Statement of Operations and Comprehensive Loss (in thousands) As reported Adjustment As revised Other income (expense) (43 ) 24 (19 ) Unrealized gains (losses) on marketable securities - (24 ) (24 ) (43 ) - (43 ) Consolidated Statement of Cash Flows (in thousands) As reported Adjustment As revised Net realized and unrealized gains on marketable securities - 13 13 Net cash provided in operations - 13 13 Purchases of marketable securities - (18,850 ) (18,850 ) Proceeds from sales of marketable securities - 3,350 3,350 Net cash used in investing activities - (15,500 ) (15,500 ) Beginning cash and cash equivalents 14,437 - 14,437 Ending cash and cash equivalents $ 24,205 $ (15,463 ) $ 8,742

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14—Subsequent Events On January 4, 2023, shareholder approval was secured by the Company for the issuance of the common stock warrants issued in conjunction with the Company’s October 2022 financing. During 2023, through February 24, 2023, there were 660,046 common stock warrants which had converted into 660,046 shares of common stock at a $0 exercise price with no proceeds received by the Company. At-The-Market Offering On , we entered into a Sales Agreement with Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to create an at-the-market offering program under which we may offer and sell shares having an aggregate offering price of up to $ million . Ladenburg is entitled to a commission at a fixed commission rate equal to up to 3% of the gross proceeds.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Nature of Business and Significant Accounting Policies [Abstract]
Going Concern	Going Concern The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern. During the years ended December 31, 2022 and 2021, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of December 31, 2022, the Company had an accumulated deficit of $267.4 million, and it expects to incur losses for the immediate future. To date, the Company has been funded by equity financings, and although the Company believes that it will be able to successfully fund its operations, there can be no assurance that it will be able to do so or that it will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through at least twelve months from the report date. The Company became a revenue-generating company after acquiring the Aquadex Business in August 2016. The Company expects to incur additional losses in the near-term as it grows the Aquadex Business, including investments in expanding its sales and marketing capabilities, purchasing inventory, manufacturing components, investing in clinical research and new product development, and complying with the requirements related to being a U.S. public company. To become and remain profitable, the Company must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require the Company to succeed in training personnel at hospitals and effectively and efficiently manufacturing, marketing, and distributing the Aquadex System and related components. There can be no assurance that the Company will succeed in these activities, and it may never generate revenues sufficient to achieve profitability. During 2021 and through December 31, 2022, the Company closed on underwritten public equity offerings for aggregate net proceeds of approximately $37.3 million after deducting the underwriting discounts and commissions and other costs associated with the offerings . See Note 4—Stockholders’ Equity for additional related disclosure The Company believes that its existing capital resources will be sufficient to support its operating plan through December 31, 2023. However, the Company may seek to raise additional capital to support its growth or other strategic initiatives through debt, equity, or a combination thereof. There can be no assurance we will be successful in raising additional capital.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements include the accounts of Nuwellis, Inc. and its wholly owned subsidiary, Sunshine Heart Ireland Limited. All intercompany accounts and transactions between consolidated entities have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and term deposits with original maturities of three months or less. The carrying value of these instruments approximates fair value. The balances, at times, may exceed federally insured limits. The Company has not experienced any losses on its cash and cash equivalents.
Marketable securities	Marketable securities The Company’s marketable securities typically consist of investment-grade, U.S. dollar-denominated fixed and floating-rate debt, which are classified as available-for-sale and included in current assets. Most marketable securities mature within twelve months from their date of purchase and generally are intended to fund current operations. Securities are valued based on market prices for similar assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of shareholders’ equity in accumulated other comprehensive income (loss). Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis and impairment is indicated, it must be determined whether the impairment is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of shareholders’ equity in accumulated other comprehensive gain (loss). There were no other than temporary unrealized losses as of December 31, 2022.
Accounts Receivable	Accounts Receivable Accounts receivables are unsecured, recorded at net realizable value, and do not bear interest. The Company makes judgments as to its ability to collect outstanding receivables based upon significant patterns of collectability, historical experience, and management’s evaluation of specific accounts, and it will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers’ financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. To date the Company has not experienced any write-offs or significant deterioration in the aging of its accounts receivable, and therefore, no allowance for doubtful accounts was considered necessary as of December 31, 2022 or December 31, 2021. As of December 31, 2022, two customers represented 15% and 10% of the total accounts receivable balance. As of December 31, 2021, two customers represented 12% and 11% of the total accounts receivable balance.
Inventories	Inventories Inventories are recorded at the lower of cost or net realizable value using the first-in, first-out method. Overhead is allocated to manufactured finished goods inventory based on the normal capacity of the Company’s production facilities. Abnormal amounts of overhead, if any, are expensed as incurred. On a regular basis, the Company reviews its inventory and identifies that which is excess, slow moving, and obsolete by considering factors such as inventory levels and expected product life. A reserve is established for any identified excess, slow moving, and obsolete inventory through a charge to cost of goods sold. Inventories consisted of the following as of December 31: (Dollars in thousands) 2022 2021 Finished Goods $ 993 $ 1,527 Work in Process 204 276 Raw Materials 1,609 1,281 Inventory Reserves (145 ) (241 ) Total $ 2,661 $ 2,843
Other Current Assets	Other Current Assets Other current assets represent prepayments and deposits made by the Company.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is computed based upon the estimated useful life of the respective asset. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Repairs and maintenance cost is expensed as incurred. The cost and accumulated depreciation of property, plant and equipment retired or otherwise disposed of is removed from the related accounts, and any residual values are charged to expense. Depreciation expense has been calculated using the following estimated useful lives: Production Equipment 3-7 years Office Furniture and Fixtures 3-5 years Computer Software and Equipment 3-4 years Loaners and demo equipment 1-5 years Leasehold improvements 3-5 years Depreciation expense was $372,000 and $488,000 for the years ended December 31, 2022 and 2021, respectively. Property, plant and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group, further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the fair value of the asset or asset group is exceeded by its carrying amount. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets or asset groups, and accordingly, actual results could vary significantly from such estimates. The Company continues to report operating losses and negative cash flows from operations, both of which it considers to be indicators of potential impairment. Therefore, the Company evaluates its long-lived assets for potential impairment at each reporting period. The Company has concluded that its cash flows from the various long-lived assets are highly interrelated and, as a result, the Company consists of a single asset group. As the Company expects to continue incurring losses in the foreseeable future, the undiscounted cash flow step was bypassed, and the Company proceeded to fair value the asset group. . There have been no impairment losses recognized for the years ended December 31, 2022 or 2021.
Accounts Payable and Accrued Liabilities	Accounts Payable and Accrued Liabilities Accrued liabilities includes amounts accrued but not invoiced related to payments owed for licensing agreements, director fees, and others.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers
Foreign Currency Translation	Foreign Currency Translation Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Assets and liabilities of foreign operations are translated at period-end exchange rates with the impacts of foreign currency translation recorded in cumulative translation adjustment, a component of accumulated other comprehensive income. Foreign currency transactions gains and losses are included in other expense, net in the consolidated statements of operations and other comprehensive loss.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes all share-based payments to employees, directors, and consultants, including grants of stock options and common stock awards, in the consolidated statement of operations and comprehensive loss as an operating expense based on their fair values as established at the grant date. Equity instruments issued to non-employees include common stock awards or warrants to purchase shares of our common stock. These common stock awards or warrants are either fully vested and exercisable at the date of grant or vest over a certain period during which services are provided. The Company expenses the fair market value of fully vested awards at the time of grant, and of unvested awards over the period in which the related services are received. The Company computes the estimated fair values of stock options using the Black-Scholes option pricing model. Market price at the date of grant is used to calculate the fair value of common stock awards. Stock-based compensation expense is based on awards ultimately expected to vest and is reduced for forfeitures. See Note 5—Stock-Based Compensation, for further information regarding the assumptions used to calculate the fair value of stock-based compensation.
Income Taxes	Income Taxes Deferred income taxes are provided on a liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
Loss per Share	Loss per share Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. The net loss allocable to common stockholders for the year ended December 31, 2021, includes a deemed dividend of $75,000 that resulted from the change in the exercise price of warrants as a result of the March 2021 and September 2021 public offerings. (see Note 4 — Stockholders’ Equity) Diluted earnings per share is computed based on the net loss allocable to common stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each year presented: December 31, 2022 2021 Stock options 10,485 7,481 Warrants to purchase common stock 679,244 16,299 Series F convertible preferred stock 5,080 50,800 Series I convertible preferred stock 10,493 — Total 705,302 74,580 The following table reconciles reported net loss with reported net loss per share for the years ended December 31: (in thousands, except per share amounts) 2022 2021 Net loss $ (14,525 ) $ (19,545 ) Deemed dividend to preferred stockholders (see Note 4) — (75 ) Net loss after deemed dividend (14,525 ) (19,620 ) Weighted average shares outstanding 174 69 Basic and diluted loss per share $ (83.55 ) $ (285.36 )
Research and Development	Research and Development Research and development (R&D) costs include activities related to development, design, and testing improvements of the Aquadex System and potential related new products. These R&D costs also include expenses related to clinical research that the Company may sponsor or conduct to enhance understanding of the product and its use. R&D costs are expensed as incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, “Financial Instruments – Credit Losses.” This ASU added a new impairment model (known as the current expected credit loss (“CECL”) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses. The CECL model applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses, and entities will need to measure expected credit losses on assets that have a low risk of loss. As a smaller reporting company pursuant to Rule 12b-2 of the Securities Exchange Act of 1934, as amended, these changes become effective for the Company on January 1, 2023. Management has evaluated the potential impact of these changes on the consolidated financial statements of the Company and does not anticipate it will have any impact to the Company’s consolidated financial statements. The Company evaluates subsequent events through the date the consolidated financial statements are filed for events requiring adjustment to or disclosure in the consolidated financial statements.

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Nature of Business and Significant Accounting Policies [Abstract]
Inventories	Inventories consisted of the following as of December 31: (Dollars in thousands) 2022 2021 Finished Goods $ 993 $ 1,527 Work in Process 204 276 Raw Materials 1,609 1,281 Inventory Reserves (145 ) (241 ) Total $ 2,661 $ 2,843
Estimated Useful Lives	Depreciation expense has been calculated using the following estimated useful lives: Production Equipment 3-7 years Office Furniture and Fixtures 3-5 years Computer Software and Equipment 3-4 years Loaners and demo equipment 1-5 years Leasehold improvements 3-5 years
Potential Shares of Common Stock not Included in Diluted Net Loss Per Share	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each year presented: December 31, 2022 2021 Stock options 10,485 7,481 Warrants to purchase common stock 679,244 16,299 Series F convertible preferred stock 5,080 50,800 Series I convertible preferred stock 10,493 — Total 705,302 74,580
Reconciles Reported Net Loss with Reported Net Loss Per Share	The following table reconciles reported net loss with reported net loss per share for the years ended December 31: (in thousands, except per share amounts) 2022 2021 Net loss $ (14,525 ) $ (19,545 ) Deemed dividend to preferred stockholders (see Note 4) — (75 ) Net loss after deemed dividend (14,525 ) (19,620 ) Weighted average shares outstanding 174 69 Basic and diluted loss per share $ (83.55 ) $ (285.36 )

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment were as follows: (in thousands) December 31, 2022 December 31, 2021 Production Equipment $ 1,360 $ 1,321 Loaners and Demo Equipment 1,444 1,364 Computer Software and Equipment 719 714 Office Furniture & Fixtures 375 364 Leasehold Improvements 253 245 Total 4,151 4,008 Accumulated Depreciation (3,171 ) (2,820 ) $ 980 $ 1,188

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Stock-Based Compensation [Abstract]
Summary of Stock-Based Compensation Expense	The following table summarizes the stock-based compensation expense that was recognized in the consolidated statements of operations for the years ended December 31, (Dollars in thousands) 2022 2021 Selling, general and administrative $ 784 $ 1,171 Research and development 78 143 Total $ 862 $ 1,314
Summary of Plan Stock Option Activity	The following is a summary of the Plans’ stock option activity during the years ended December 31: 2022 2021 Options Outstanding Weighted Average Exercise Price Options Outstanding Weighted Average Exercise Price Beginning Balance 7,481 $ 656.05 144 $ 40,534.00 Granted 5,833 83.96 9,081 444.83 Exercised — — — — Forfeited/expired (2,829 ) 410.34 (1,744 ) 2,332.06 Outstanding at December 31 10,485 $ 404.08 7,481 $ 656.05 Vested at December 31 3,531 $ 727.26 409 $ 4,218.40
Weighted Average Assumptions used in Black-Scholes Option Pricing Model	The following table provides the weighted average assumptions used in the Black-Scholes option pricing model for the years ended December 31: 2022 2021 Expected dividend yield 0 % 0 % Risk-free interest rate 2.13 % 1.19 % Expected volatility 132.48 % 131.03 % Expected life (in years) 6.15 6.21

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value of Financial Instruments [Abstract]
Available-for-Sale Marketable Securities Measured at Fair Value on Recurring Basis	The available-for-sale marketable securities primarily consist of investment-grade, U.S. dollar-denominated fixed and floating-rate debt, measured at fair value on a recurring basis. 2022 2021 (Dollars in thousand s Fair Value Level 1 Fair Value Level 1 Marketable securities $ 569 $ 569 $ 15,463 $ 15,463
Roll-Forward of Fair Value of Level 3 Warrants	The following is a roll-forward of the fair value of Level 3 warrants: (in thousands) October 18, 2022 warrant issuance $ 18,695 Change in fair value (11,827 ) Ending balance December 31, 2022 $ 6,868
Fair Value Assumptions	Fair values were calculated using the following assumptions: Oct. 18, 2022 Dec. 31, 2022 Risk-free interest rates, adjusted for continuous compounding 4.16 % 3.97 % Term (years) 6.18 6.11 Expected volatility 141.5 % 145.3 % Dates and probability of future equity raises various various

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Domestic and Foreign Income (Loss) Before Income Taxes	Domestic and foreign income (loss) before income taxes consists of the following for the years ended December 31: (in thousands) 2022 2021 Domestic $ (14,551 ) $ (19,582 ) Foreign 35 37 Loss before income taxes $ (14,516 ) $ (19,545 )
Components of Income Tax Expense	The components of income tax expense consist of the following for the years ended December 31: (in thousands) 2022 2021 Current: United States and state $ — $ — Foreign, net (9 ) (9 ) Deferred: United States and state — — Foreign — — Total income tax expense $ (9 ) $ (9 )
Actual Income Tax Expense Differs from Statutory Federal Income Tax Expense	Actual income tax expense differs from statutory federal income tax expense as follows for the years ended December 31: (in thousands) 2022 2021 Statutory federal income tax benefit $ 3,048 $ 4,109 State tax benefit, net of federal taxes 783 560 Foreign tax (1 ) (1 ) Nondeductible/nontaxable items 548 (220 ) Other (41 ) 406 Valuation allowance (increase) decrease (4,346 ) (4,863 ) Total income tax expense $ (9 ) $ (9 )
Deferred Taxes	Deferred taxes consist of the following as of December 31: (in thousands) 2022 2021 Deferred tax assets: Noncurrent: Accrued leave $ 397 $ 59 Stock based compensation 360 368 Net operating loss carryforward 45,405 42,363 Other 42 131 Intangibles 1,786 723 R&D credit carryforward 531 531 Total deferred tax assets 48,521 44,175 Less: valuation allowance (48,521 ) (44,175 ) Total $ — $ —

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Operating Leases [Abstract]
Cost Components of Operating Leases	The cost components of the Company’s operating lease were as follows for the year ended December 31: (in thousands) 2022 2021 Operating lease cost $ 238 $ 219 Variable lease cost 127 123 Total $ 365 $ 342
Maturities of Lease Liability	Maturities of our lease liability for the Company’s operating lease are as follows as of December 31: (in thousands) 2022 2023 $ 249 2024 257 2025 264 2026 272 2027 69 Total lease payments 1,111 Less: Interest (155 ) Present value of lease liability $ 956

Revision and Immaterial Corre_2

Revision and Immaterial Correction of an Error in Previously Issued Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2022
Revision and Immaterial Correction of an Error in Previously Issued Financial Statements [Abstract]
Immaterial Correction of Error on Consolidated Financial Statements	The effect of the immaterial correction of an error on our previously filed audited consolidated financial statements as of December 31, 2021 and for the year then ended is as follows: (in thousands) December Consolidated Balance Sheet As reported Adjustment As revised Cash and cash equivalents $ 24,205 $ (15,463 ) $ 8,742 Marketable securities - 15,463 15,463 Total Current Assets 28,126 - 28,126 Consolidated Statement of Operations and Comprehensive Loss (in thousands) As reported Adjustment As revised Other income (expense) (43 ) 24 (19 ) Unrealized gains (losses) on marketable securities - (24 ) (24 ) (43 ) - (43 ) Consolidated Statement of Cash Flows (in thousands) As reported Adjustment As revised Net realized and unrealized gains on marketable securities - 13 13 Net cash provided in operations - 13 13 Purchases of marketable securities - (18,850 ) (18,850 ) Proceeds from sales of marketable securities - 3,350 3,350 Net cash used in investing activities - (15,500 ) (15,500 ) Beginning cash and cash equivalents 14,437 - 14,437 Ending cash and cash equivalents $ 24,205 $ (15,463 ) $ 8,742

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies, Liquidity, Accounts Receivable and Inventories (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Customer	Dec. 31, 2021 USD ($) Customer
Liquidity [Abstract]
Accumulated deficit	$ (267,417)	$ (252,892)
Net proceeds from issuance of public offering	$ 37,300
Accounts Receivable [Abstract]
Accounts receivables maximum credit period from invoice date	30 days
Allowance for doubtful accounts	$ 0	0
Inventories [Abstract]
Finished Goods	993	1,527
Work in Process	204	276
Raw Materials	1,609	1,281
Inventory Reserves	(145)	(241)
Total	$ 2,661	$ 2,843
Accounts Receivable [Member]
Revenue, Performance Obligation [Abstract]
Number of major customers | Customer	2	2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage	15%	12%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage	10%	11%

Nature of Business and Signif_5

Nature of Business and Significant Accounting Policies, Property, Plant and Equipment and Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Customer	Dec. 31, 2021 USD ($) Customer
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 372,000	$ 488,000
Impairment losses recognized	$ 0	$ 0
Production Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Production Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	7 years
Office Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Office Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years
Computer Software and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Computer Software and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	4 years
Loaners and Demo Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	1 year
Loaners and Demo Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	3 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Abstract]
Estimated useful lives	5 years
ASC 606 [Member] | Net Sales [Member]
Revenue Recognition [Abstract]
Number of major customers | Customer	1	2
ASC 606 [Member] | Customer One [Member] | Net Sales [Member] | Customer Concentration Risk [Member]
Revenue Recognition [Abstract]
Concentration risk percentage	12.50%	12.30%
ASC 606 [Member] | Customer Two [Member] | Net Sales [Member] | Customer Concentration Risk [Member]
Revenue Recognition [Abstract]
Concentration risk percentage		10.70%

Nature of Business and Signif_6

Nature of Business and Significant Accounting Policies, Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Loss per share [Abstract]
Net deemed dividends resulting from subsequent reduction in exercise price of warrants		$ 75,000
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	705,302	74,580
Reconciliation of reported net loss with reported net loss per share [Abstract]
Net loss	$ (14,525)	$ (19,545)
Deemed dividend to preferred shareholders (see Note 4)	0	(75)
Net loss after deemed dividend	$ (14,525)	$ (19,620)
Weighted average shares outstanding - basic (in shares)	174,000	69,000
Weighted average shares outstanding - diluted (in shares)	174,000	69,000
Basic loss per share (in dollars per share)	$ (83.55)	$ (285.36)
Diluted loss per share (in dollars per share)	$ (83.55)	$ (285.36)
Stock Options [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	10,485	7,481
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	679,244	16,299
Series F Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	5,080	50,800
Series I Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share (in shares)	10,493	0

Revenue Recognition (Details)

Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]
Expected timing of satisfaction, period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Abstract]
Expected timing of satisfaction, period	1 year
Sales Revenue [Member] | Customer Concentration Risk [Member] | ASC 606 [Member] | Maximum [Member]
Revenue, Performance Obligation [Abstract]
Concentration risk percentage	1%	1%

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	$ 4,151	$ 4,008
Accumulated Depreciation	(3,171)	(2,820)
Property, Plant and Equipment, Net	980	1,188
Production Equipment [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	1,360	1,321
Loaners and Demo Equipment [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	1,444	1,364
Computer Software and Equipment [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	719	714
Office Furniture & Fixtures [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	375	364
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross [Abstract]
Property, Plant and Equipment, Gross	$ 253	$ 245

Stockholders' Equity (Details)

Stockholders' Equity (Details)

12 Months Ended

Dec. 08, 2022

Dec. 05, 2022

Oct. 18, 2022 USD ($) $ / shares shares

Sep. 17, 2021 USD ($) $ / shares shares

Mar. 19, 2021 USD ($) $ / shares shares

Aug. 21, 2020 USD ($) $ / shares shares

May 05, 2020 USD ($) $ / shares shares

Apr. 01, 2020 USD ($) shares

Mar. 23, 2020 USD ($) $ / shares shares

Jan. 28, 2020 USD ($) $ / shares shares

Mar. 12, 2019 $ / shares

Nov. 27, 2017 USD ($) $ / shares shares

Dec. 31, 2022 USD ($) shares

Dec. 31, 2021 USD ($) shares

Dec. 31, 2020 USD ($) shares

Sep. 30, 2022 $ / shares

Apr. 02, 2020 $ / shares shares

Nov. 06, 2019 $ / shares

Oct. 25, 2019 $ / shares

May 30, 2019 $ / shares shares

Jul. 03, 2018 $ / shares

Class of Stock Disclosures [Abstract]

Warrants exercised to purchase common stock (in shares)

4,552,000

Proceeds from warrant exercises | $

$ 0

$ 1,000

$ 4,100,000

Preferred stock, shares outstanding (in shares)

0

0

Reverse stock split

0.01

Minimum [Member]

Class of Stock Disclosures [Abstract]

Reverse stock split

0.02

Maximum [Member]

Class of Stock Disclosures [Abstract]

Reverse stock split

0.01

January 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

5,855,000

Exercise price of warrants (in dollars per share) | $ / shares

$ 25

$ 900

$ 1,650

$ 250

Issuance of common stock, net (in shares)

2,015,000

Public offering price (in dollars per share) | $ / shares

$ 1,650

Gross proceeds from public stock offering | $

$ 9,700,000

Net proceeds from public stock offering | $

8,600,000

Down-round protection in connection with re-pricing of warrants | $

200,000

Beneficial conversion amount | $

$ 1,600,000

March 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

1,387,000

Exercise price of warrants (in dollars per share) | $ / shares

$ 1,118

Issuance of common stock, net (in shares)

1,387,000

Public offering price (in dollars per share) | $ / shares

$ 900

Gross proceeds from public stock offering | $

$ 1,200,000

Net proceeds from public stock offering | $

$ 1,000,000

Warrant expiry period

5 years 6 months

Warrants exercisable period

6 months

April 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

855,000

Exercise price of warrants (in dollars per share) | $ / shares

$ 1,115

Issuance of common stock, net (in shares)

1,710,000

Public offering price (in dollars per share) | $ / shares

$ 1,302

Gross proceeds from public stock offering | $

$ 2,200,000

Warrant expiry period

5 years 6 months

May 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

600,000

Exercise price of warrants (in dollars per share) | $ / shares

$ 1,230

Issuance of common stock, net (in shares)

1,199,000

Public offering price (in dollars per share) | $ / shares

$ 1,418

Gross proceeds from public stock offering | $

$ 1,700,000

Warrant expiry period

5 years 6 months

August 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

10,647,000

Public offering price (in dollars per share) | $ / shares

$ 1,350

Gross proceeds from public stock offering | $

$ 14,400,000

Net proceeds from public stock offering | $

$ 13,000,000

Number of shares issuable on the exercise of warrants (in shares)

10,647,000

Warrant expiry period

5 years

March 2021 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

37,958,000

Gross proceeds from public stock offering | $

$ 20,900,000

Net proceeds from public stock offering | $

$ 18,900,000

September 2021 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

40,056,000

Gross proceeds from public stock offering | $

$ 10,000,000

Net proceeds from public stock offering | $

$ 9,000,000

October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Gross proceeds from public stock offering | $

$ 11,000,000

Net proceeds from public stock offering | $

$ 9,400,000

Warrants to Purchase Common Stock [Member]

Class of Stock Disclosures [Abstract]

Number of warrants vested (in shares)

0

Warrants to Purchase Common Stock [Member] | Consultant [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

33,000

Exercise price of warrants (in dollars per share) | $ / shares

$ 9,540

Common Stock [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

209,940

78,014

Conversion of preferred stock into common stock (in shares)

221,078

Common Stock [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

209,940,000

Series F Convertible Preferred Stock [Member]

Class of Stock Disclosures [Abstract]

Gross proceeds from issuance of convertible preferred stock | $

$ 18,000,000

Net proceeds from issuance of convertible preferred stock | $

$ 16,200,000

Conversion price (in dollars per share) | $ / shares

$ 189,000

$ 89,040

Number of consecutive trading days considered for expiration

20 days

Number of consecutive trading days

30 days

Preferred stock issued (in shares)

18,000

127

127

Number of shares issuable on conversion of preferred stock (in shares)

96,000

Preferred stock, shares outstanding (in shares)

127

127

Aggregate cash placement fee

8%

Series F Convertible Preferred Stock [Member] | Minimum [Member]

Class of Stock Disclosures [Abstract]

Percentage of volume weighted average price of common stock

300%

Trading volume for each trading day | $

$ 200,000

Series F Convertible Preferred Stock [Member] | March 2019 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 15,750

Series F Convertible Preferred Stock [Member] | October 2019 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 4,230

Series F Convertible Preferred Stock [Member] | November 2019 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 2,983

Series F Convertible Preferred Stock [Member] | January 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 1,650

Exercise price of warrants (in dollars per share) | $ / shares

900

Series F Convertible Preferred Stock [Member] | March 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 900

Series F Convertible Preferred Stock [Member] | March 2021 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 550

Exercise price of warrants (in dollars per share) | $ / shares

$ 550

Series F Convertible Preferred Stock [Member] | September 2021 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 250

Exercise price of warrants (in dollars per share) | $ / shares

$ 250

Series F Convertible Preferred Stock [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 25

$ 250

Series F Convertible Preferred Stock [Member] | Warrants to Purchase Common Stock [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

191,000

Series F Convertible Preferred Stock [Member] | Warrant Series 1 [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

16

Exercise price of warrants (in dollars per share) | $ / shares

$ 189,000

Series F Convertible Preferred Stock [Member] | Warrant Series 2 [Member]

Class of Stock Disclosures [Abstract]

Warrants to purchase shares of common stock (in shares)

4

Exercise price of warrants (in dollars per share) | $ / shares

$ 189,000

Series H Preferred Stock [Member]

Class of Stock Disclosures [Abstract]

Conversion price (in dollars per share) | $ / shares

$ 1,650

Preferred stock, shares outstanding (in shares)

0

Maximum percentage of the applicable Unit offering price, by which exercise price can be lower than adjustment

10%

Conversion of preferred stock into common stock (in shares)

115,173

Series H Preferred Stock [Member] | January 2020 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

115,173,000

Series I Preferred Stock [Member]

Class of Stock Disclosures [Abstract]

Preferred stock issued (in shares)

1,049,280

0

Preferred stock, shares outstanding (in shares)

1,049,280

0

Series I Preferred Stock [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

23,157,124,000

Number of share in one unit (in shares)

1

Class A Unit [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

209,940,000

Common stock offering price per share (in dollars per share) | $ / shares

$ 25

Number of share in one unit (in shares)

1

Common stock exercise price per share (in dollars per share) | $ / shares

$ 25

Class A Unit [Member] | Warrants [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Number of share in one unit (in shares)

1.5

Class B Unit [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Issuance of common stock, net (in shares)

23,157,124,000

Common stock offering price per share (in dollars per share) | $ / shares

$ 0.25

Common stock exercise price per share (in dollars per share) | $ / shares

$ 0

Class B Unit [Member] | Warrants [Member] | October 2022 Offering [Member]

Class of Stock Disclosures [Abstract]

Number of share in one unit (in shares)

1.5

Stock-Based Compensation, Stock

Stock-Based Compensation, Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 862,000	$ 1,314,000
Minimum [Member]
Additional Disclosures [Abstract]
Award vesting period	1 year
Maximum [Member]
Additional Disclosures [Abstract]
Award vesting period	4 years
Selling, General and Administrative [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 784,000	1,171,000
Research and Development [Member]
Stock-Based Compensation Expense Items [Abstract]
Stock-based compensation expense	$ 78,000	$ 143,000
Stock Options [Member]
Stock Options Activity [Roll Forward]
Outstanding, beginning balance (in shares)	7,481	144
Granted (in shares)	5,833	9,081
Exercised (in shares)	0	0
Forfeited/expired (in shares)	(2,829)	(1,744)
Outstanding, ending balance (in shares)	10,485	7,481
Vested at the end of the year (in shares)	3,531	409
Weighted Average Exercise Price [Abstract]
Outstanding, beginning balance (in dollars per share)	$ 656.05	$ 40,534
Granted (in dollars per share)	83.96	444.83
Exercised (in dollars per share)	0	0
Forfeited/expired (in dollars per share)	410.34	2,332.06
Outstanding, ending balance (in dollars per share)	404.08	656.05
Vested at the end of the year (in dollars per share)	$ 727.26	$ 4,218.4
Weighted Average Remaining Contractual Term [Abstract]
Options outstanding, weighted average remaining contractual life	8 years 9 months 14 days	8 years 9 months 14 days
Options vested, weighted average remaining contractual life	8 years 7 months 17 days	8 years 7 months 17 days
Aggregate Intrinsic Value [Abstract]
Fair value of options, vested	$ 1,100,000	$ 700,000
Weighted Average Assumptions used in Black-Scholes Option Pricing Model [Abstract]
Expected dividend yield	0%	0%
Risk-free interest rate	2.13%	1.19%
Expected volatility	132.48%	131.03%
Expected life	6 years 1 month 24 days	6 years 2 months 15 days
Additional Disclosures [Abstract]
Weighted-average fair value of options granted (in dollars per share)	$ 76.05	$ 396.17
Total unrecognized compensation costs related to non-vested stock option awards	$ 1,300,000
Unrecognized compensation costs related to non-vested stock option awards, recognition life	2 years 6 months 14 days

Stock-Based Compensation, Warra

Stock-Based Compensation, Warrants (Details) - Warrants [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Abstract]
Warrants outstanding (in shares)	679,244	16,299
Minimum [Member]
Class of Warrant or Right [Abstract]
Exercise price of warrants (in dollars per share)	$ 25
Maximum [Member]
Class of Warrant or Right [Abstract]
Exercise price of warrants (in dollars per share)	$ 189,000
Warrants exercisable period	5 years 9 months 18 days

Fair Value of Financial Instr_3

Fair Value of Financial Instruments, Available-for-Sale Marketable Securities Measured at Fair Value on Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Available-for-sale marketable securities [Abstract]
Marketable securities	$ 569	$ 15,463
Level 1 [Member]
Available-for-sale marketable securities [Abstract]
Marketable securities	$ 569	$ 15,463

Fair Value of Financial Instr_4

Fair Value of Financial Instruments, Roll-Forward of Fair Value of Level 3 Warrants (Details) - Warrant [Member] $ in Thousands	2 Months Ended
	Dec. 31, 2022 USD ($)
Roll-Forward of Fair Value of Level 3 Warrants [Roll Forward]
Beginning balance	$ 18,695
Change in fair value	(11,827)
Ending balance	$ 6,868

Fair Value of Financial Instr_5

Fair Value of Financial Instruments, Fair Values Assumptions (Details)		12 Months Ended
	Oct. 18, 2022	Dec. 31, 2022
Valuation Technique and Input, Description [Abstract]
Dates and probability of future equity raises	various	various
Risk-Free Interest Rate, Adjusted for Continuous Compounding [Member]
Valuation Technique and Input, Description [Abstract]
Measurement input	0.0416	0.0397
Term [Member]
Valuation Technique and Input, Description [Abstract]
Term	6 years 2 months 4 days	6 years 1 month 9 days
Expected Volatility [Member]
Valuation Technique and Input, Description [Abstract]
Measurement input	1.415	1.453

Income Taxes, Domestic and Fore

Income Taxes, Domestic and Foreign Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Domestic and foreign income (loss) before income taxes [Abstract]
Domestic	$ (14,551)	$ (19,582)
Foreign	35	37
Loss before income taxes	$ (14,516)	$ (19,545)

Income Taxes, Components of Inc

Income Taxes, Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current [Abstract]
United States and state	$ 0	$ 0
Foreign, net	(9)	(9)
Deferred [Abstract]
United States and state	0	0
Foreign	0	0
Total income tax expense	$ (9)	$ (9)

Income Taxes, Effective Income

Income Taxes, Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Effective income tax rate reconciliation [Abstract]
Statutory federal income tax benefit	$ 3,048	$ 4,109
State tax benefit, net of federal taxes	783	560
Foreign tax	(1)	(1)
Nondeductible/nontaxable items	548	(220)
Other	(41)	406
Valuation allowance (increase) decrease	(4,346)	(4,863)
Total income tax expense	$ (9)	$ (9)

Income Taxes, Deferred Taxes an

Income Taxes, Deferred Taxes and Other Information (Details) $ in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 AUD ($)
Noncurrent [Abstract]
Accrued leave	$ 397	$ 59
Stock based compensation	360	368
Net operating loss carryforward	45,405	42,363
Other	42	131
Intangibles	1,786	723
R&D credit carryforward	531	531
Total deferred tax assets	48,521	44,175
Less: valuation allowance	(48,521)	(44,175)
Total	0	0
Operating Loss Carryforwards [Abstract]
Increase in valuation allowance	4,300	4,900
Unrecognized Tax Benefits [Abstract]
Uncertain tax positions	0	0
Penalties and Interest Accrued [Abstract]
Interest and penalties accrued on uncertain tax positions	$ 0	$ 0
Earliest Tax Year [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards, expiration date	Dec. 31, 2024
Latest Tax Year [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards, expiration date	Dec. 31, 2038
Federal [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards	$ 198,100
Net operating loss (NOL) carryforwards with expiration date	120,100
Net operating loss (NOL) carryforwards with no expiration date	78,000
State [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards	$ 53,800
Australian [Member]
Operating Loss Carryforwards [Abstract]
Net operating loss (NOL) carryforwards			$ 0

Operating Leases (Details)

Operating Leases (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / ft² ft²	Dec. 31, 2021 USD ($)
Operating Leases [Abstract]
Area of property leased under operating lease | ft²	23,000
Monthly rent and common area maintenance charges	$ 31,000
Annual base rent (per square foot) | $ / ft²	10.5
Cost Components of Operating Leases [Abstract]
Operating lease cost	$ 238,000	$ 219,000
Variable lease cost	127,000	123,000
Total	365,000	$ 342,000
Maturities of Lease Liability [Abstract]
2023	249,000
2024	257,000
2025	264,000
2026	272,000
2027	69,000
Total lease payments	1,111,000
Less: Interest	(155,000)
Present value of lease liability	$ 956,000
Remaining lease term	4 years 3 months	5 years 3 months
Discount rate	6.25%	7.50%
Operating cash outflows from operating lease	$ 238,000	$ 219,000
Minimum [Member]
Operating Leases [Abstract]
Annual increase per square foot (in dollars per square foot) | $ / ft²	0.32
Maximum [Member]
Operating Leases [Abstract]
Annual increase per square foot (in dollars per square foot) | $ / ft²	0.34

Finance Lease Liability (Detail

Finance Lease Liability (Details)	Dec. 31, 2020 USD ($)
Finance Lease Liability [Abstract]
Value of finance lease equipment	$ 98,000
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net
Principal amount under lease agreement	$ 93,000
Implied interest rate	7.50%
Finance lease term	39 months

Commitments and Contingencies (

Commitments and Contingencies (Details)		12 Months Ended
	Aug. 05, 2021 USD ($) Installment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Employee Retirement Plan [Abstract]
Employer's matching contribution		$ 185,000	$ 255,000
Koronis Biomedical Corporation [Member]
Commitments and Contingencies [Abstract]
Amount of grant approval received	$ 1,700,000
Non-refundable technology license fee	$ 428,160
Number of equal monthly installments | Installment	12
Research and Development Expense [Member] | Koronis Biomedical Corporation [Member]
Commitments and Contingencies [Abstract]
Non-refundable technology license fee expenses			$ 428,160
Accounts Payable [Member] | Koronis Biomedical Corporation [Member]
Commitments and Contingencies [Abstract]
Non-refundable technology license fee		$ 178,400

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Amount of related party transactions	$ 0	$ 0

Segment and Geographic Inform_2

Segment and Geographic Information (Details)	12 Months Ended
	Dec. 31, 2022 Segment
Segment and Geographic Information [Abstract]
Number of reportable segments	1

Revision and Immaterial Corre_3

Revision and Immaterial Correction of an Error in Previously Issued Financial Statements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Consolidated Balance Sheet [Abstract]
Cash and cash equivalents	$ 17,737	$ 8,742
Marketable securities	569	15,463
Total current assets	22,769	28,126
Consolidated Statement of Operations and Comprehensive Loss [Abstract]
Other income (expense)	75	(19)
Unrealized gains (losses) on marketable securities	80	(24)
Total comprehensive loss		(43)
Consolidated Statement of Cash Flows [Abstract]
Net realized and unrealized gains on marketable securities	124	13
Net cash used in operating activities		13
Purchases of marketable securities	0	(18,850)
Proceeds from sales of marketable securities	14,850	3,350
Net cash provided (used) in investing activities		(15,500)
Cash and cash equivalents - beginning of year	8,742	14,437
Cash and cash equivalents - end of year	17,737	8,742
As Reported [Member]
Consolidated Balance Sheet [Abstract]
Cash and cash equivalents		24,205
Marketable securities		0
Total current assets		28,126
Consolidated Statement of Operations and Comprehensive Loss [Abstract]
Other income (expense)		(43)
Unrealized gains (losses) on marketable securities		0
Total comprehensive loss		(43)
Consolidated Statement of Cash Flows [Abstract]
Net realized and unrealized gains on marketable securities		0
Net cash used in operating activities		0
Purchases of marketable securities		0
Proceeds from sales of marketable securities		0
Net cash provided (used) in investing activities		0
Cash and cash equivalents - beginning of year	24,205	14,437
Cash and cash equivalents - end of year		24,205
Adjustment [Member]
Consolidated Balance Sheet [Abstract]
Cash and cash equivalents		(15,463)
Marketable securities		15,463
Total current assets		0
Consolidated Statement of Operations and Comprehensive Loss [Abstract]
Other income (expense)		24
Unrealized gains (losses) on marketable securities		(24)
Total comprehensive loss		0
Consolidated Statement of Cash Flows [Abstract]
Net realized and unrealized gains on marketable securities		13
Net cash used in operating activities		13
Purchases of marketable securities		(18,850)
Proceeds from sales of marketable securities		3,350
Net cash provided (used) in investing activities		(15,500)
Cash and cash equivalents - beginning of year	$ (15,463)	0
Cash and cash equivalents - end of year		$ (15,463)

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	2 Months Ended
	Feb. 24, 2023	Mar. 03, 2023
Common Stock Warrants Converted [Abstract]
Number of Common Stock Warrants Converted into Common Stock	660,046
Number of Shares of Common Stock Issued upon Conversion of Common Stock Warrants	660,046
Exercise price of warrants (in dollars per share)	$ 0
Ladenburg Thalmann & Co. [Member] | Maximum [Member]
At-The-Market Offering [Abstract]
Aggregate offering price		$ 10
Percentage of fixed commission rate		3%